Table 2.
Summary of HRs and their 95% CI.
| Study | Year | Region | Disease | HR | OS | HR | DFS |
|---|---|---|---|---|---|---|---|
| 95% CI | 95% CI | ||||||
| Utaijaratrasmi | 2018 | Thailand | ICC | 3.452 | 1.188-10.030 | NR | NR |
| Gopalan et al | 2018 | Australia | CRC | 1.04 | 0.45-2.38 | NR | NR |
| Fesler et al | 2018 | US | CRC | 1.57 | 1.08-2.28 | NR | NR |
| Shi et al | 2017 | China | OS | 3.281 | 2.901-3.525 | NR | NR |
| Kontos et al | 2017 | Greece | CRC | 0.56 | 0.28-1.14 | 0.185 | 0.066-0.518 |
| Li.J et al | 2016 | China | ESCC | 3.668 | 1.193-8.283 | 3.808 | 1.032-7.838 |
| Xie et al | 2015 | China | Glioma | 7.52 | 2.63-21.47 | 11.56 | 5.17-25.96 |
| Shinden et al | 2015 | Japan | BC | 2.56 | 1.03-7.18 | 1.42 | 0.75-2.69 |
| Li.F et al | 2015 | China | MM | 3.57 | 1.08-12.50 | NR | NR |
| Xiao et al | 2014 | China | CRC | 3.016 | 1.129-6.616 | 2.782 | 1.122-6.031 |
DFS, disease-free survival; HR, hazard ratio; OS, overall survival.